Product Description
ALN-4324, which targets GRB14 for the treatment of type 2 diabetes and has the potential to be the first insulin sensitizer approved in more than 30 years. At R&D Day, Alnylam will present preclinical data that demonstrate the potential for a highly desirable product profile, including approximately 90% knockdown of the target 22 days after a low-dose, subcutaneous injection, and improved insulin sensitivity without weight gain. (Sourced from: https://investors.alnylam.com/press-release?id=28716)
Mechanisms of Action: GRB14 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Alnylam
Company Location: Eastern America
Company Founding Year: 2002
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Canada, Chile, Germany, Poland, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Obesity|Overweight|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06845202 |
ALN-4324-001 | P2 |
Active, not recruiting |
Obesity|Overweight|Type 2 Diabetes |
2027-08-31 |
56% |
2026-07-24 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
NCT07465224 |
ALN-4324-002 | P2 |
Recruiting |
Type 2 Diabetes |
2027-05-28 |
52% |
2026-07-24 |
|
2024-519005-35-00 |
ALN-4324-001 | P2 |
Not yet recruiting |
Type 2 Diabetes |
2027-08-30 |
56% |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/12/2026 |
News Article |
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress |
|
05/01/2025 |
News Article |
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress |